Lupin Limited · NSE:LUPIN
Lupin — Q4 FY2021 Earnings Presentation
17 slides from Lupin's earnings presentation, May 13, 2021
Slide 1: Exchange filing cover letter
May 13, 2021 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), MUMBAI - 400 051. Dear Sirs, Sub: Q4 FY2021 Investor Presentation. Pursuant to
Slide 2: Investor Presentation Q4 FY2021
Investor Presentation Q4 FY2021 May 13, 2021
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Vinita Gupta named among Most Powerful Women in Business in India – #7 by Fortune India • India Pharma Leader Award - India Pharma 2020 and India Medical Device 2020 conference organized by FICCI and the Ministry of Chemicals and Fertilizers, GOI • Lupin ranked No.1 in
Slide 5: Q4 FY2021 Snapshot
Q4 FY2021 Snapshot Sales (INR mn, YoY Growth) Important developments Commercial Mr. Nilesh.D.Gupta India, North America, Managing Director • Sequential uptake in US generics business driven by Lupin Limited 12,866, 8% 14,952, (5%) Albuterol and new launches, amidst demand disruption in seasonal prod
Slide 6: FY2021 Highlights
FY2021 Highlights Important developments FY2021 Sales (INR mn, YoY Growth) Commercial • COVID Response: Delivered our mission of Ensuring the health and well-being of our people India, North America, while maintaining our supply of life-saving medicines 52,712, 3% 55,520, (5%) • Inhalation and Biosi
Slide 7: Strategic Vision
Strategic Vision Well Diversified Pharma Company Integrated Global Quality Culture Novel products North America NaMuscla Novel Oncology Women’s Health Franchise Research Platform Committed to building Capability building and Geographic expansion Pipeline acceleration robust specialty portfolio expan
Slide 8: Material Progress on Growth Platforms
Material Progress on Growth Platforms Injectables FY23+* Robust suite of depot, liposomal, Peptide and Iron products in development Inhalation FY21+* Women’s Accelerating Global Inhalation Health Portfolio delivery FY26+* Biosimilars FY21+* World-class R&D capabilities paired with evolving commercia
Slide 9: Financial Results Review
i LUPIN Financial Results Review
Slide 10: P&L Highlights – Q4 FY2021
P&L Highlights – Q4 FY2021 % of % of QoQ % of YoY Amount in INR mn Q4 FY21 Q3 FY21 Q4 FY20 sales sales growth sales growth Net sales 37,593 100.0% 39,173 100.0% (4.0%) 37,910 100.0% (0.8%) Other operating income 238 1,001 547 Total revenue 37,831 40,174 (5.8%) 38,457 (1.6%) Gross profit 24,417 65.0%
Slide 11: P&L Highlights – FY2021
P&L Highlights – FY2021 Amount in INR mn FY21 % of sales FY20 % of sales YoY growth Net sales 149,270 100.0% 151,428 100.0% (1.4%) Other operating income 2,360 2,320 Total revenue 151,630 153,748 (1.4%) Gross profit 95,648 64.1% 97,122 64.1% (1.5%) (excl. other operating income) EBITDA (before Fx &
Slide 12: North America
Q4FY21 North America 40% YoY 5.3% QoQ 3.7% Continuing the momentum Consolidating our position in the US1 US quarterly sales ($ mn) 212 #4 #3 #3 #3 140 6 188 195 120 #4 #5 129 5 180 100 123 122 109 4 157 80 3 60 79 83 40 65 63 2 45 51 53 20 44 1 0 0 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 Q4
Slide 13: India
Q4FY21 India 34% YoY 7.9% QoQ 5.9% India business continues to be robust Leadership across cardiac, diabetes, and respiratory India quarterly Sales (INR bn) 5 Year CAGR % Lupin Rank1 MAT MAT 12.9 13.3 13.7 12.9 Therapy Market Lupin 11.9 Mar-16 Mar-21 Acute 7% 4% 13 15 Chronic 11% 14% 5 4 Cardiac 10%
Slide 14: Other Markets
Other Markets • Germany: EUR 5.4 mn sales in Q4 FY21 EU5 • Developed EUR 29.2 mn sales in FY21 • ARVs, Inhalation and CNS are the key focus therapeutic segments • 4th largest generics player2 Australia • Growth of 14% against reference market growth of 7%2 • 4th largest Rx generics player3; Market l
Slide 15: Key Financial Metrics
Key Financial Metrics R&D (INR million) Capex (INR million) 16,634 23,101 18,509 10,470 15,731 15,538 14,324 6,851 6,276 5,710 FY17 FY18 FY19 FY20 FY21 1 FY17 FY18 FY19 FY20 FY21 Free cash flow (INR million) Net debt/ Equity 15,129 0.41 0.38 0.38 11,531 7,362 7,975 0.12 2,615 0.05 FY17 FY18 FY19 FY2
Slide 16: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence 100 23 7 Countries where Countries with Countries with OPERATIONS products are sold marketing offices subsidiaries RESEARCH 15 7 Manufacturing Sites R&D Sites ◼ 12 USFDA inspected sites ◼ 437 US ANDAs; 288 approved ◼ 30 bn+ ex
Slide 17: Thank you
Thank you Registered Office Lupin Limited, 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway Santacruz (East), Mumbai 400 055, India. www.lupin.com www.twitter.com/LupinGlobal www.linkedin.com/company/lupin/ www.facebook.com/LupinWorld/ Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051